Cutaneous reactions to rheumatological drugs.
D000305:Adrenal Cortex Hormones / Q000009:adverse effects*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000962:Antimalarials / Q000009:adverse effects*; D001379:Azathioprine / Q000009:adverse effects*; D003480:Cushing Syndrome / Q000139:chemically induced; D003520:Cyclophosphamide / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D006046:Gold / Q000009:adverse effects*; D006801:Humans; D008010:Lichen Planus / Q000139:chemically induced; D009260:Nail Diseases / Q000139:chemically induced; D010392:Pemphigus / Q000139:chemically induced; D010396:Penicillamine / Q000009:adverse effects*; D010859:Pigmentation Disorders / Q000139:chemically induced; D011537:Pruritus / Q000139:chemically induced; D011693:Purpura / Q000139:chemically induced; D012459:Salicylates / Q000009:adverse effects*; D012878:Skin Neoplasms / Q000139:chemically induced; D014581:Urticaria / Q000139:chemically induced
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000962:Antimalarials; D012459:Salicylates; D006046:Gold; D003520:Cyclophosphamide; D010396:Penicillamine; D001379:Azathioprine